Patient P-02657
Metabolic response 56 at the day-84 endpoint (observed).
Responding: response probability 59%, metabolic response 59 today; biology is not blocking the drug.
Drift detected on day 22 (inflammatory load +10); the side effect would have been reported on day 120 — 98 days of warning.
46 of 61 scheduled doses in the last 60 days are biologically confirmed (75%); 13 were logged but show no dose signature. Dose signature: resting HR +6 bpm, HRV −7 ms.
90% of 284 similar trajectories improved after GI-04; if this one does, discontinuation risk is expected to fall from 59% to ~37%. Keeping ultra-processed low is worth 5.8 GI points a day on its own. Losing this patient costs €6k; the intervention costs €45.
- 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- ✓Track each bowel movement today: time, stool form, urgency, overnight waking
- ✓A 15-minute walk after lunch
- 💊Take the dose at the same time relative to your evening meal
- 💊Electrolyte solution, one sachet after any loose stool
Partial adherence; to-dos are being skipped on symptomatic days.
GI burden above 61 for 3 days within the onset window
P-02657 is on day 160 of META-24 (LT, baseline S11): response stable, tolerance improving, GI deteriorating. Over 14 days response moved +3 and GI +5; discontinuation risk is 59%. The state is between basins, heading towards failing, after diverging from the model on day 22.
Biology sets the gain: IL6 high-expression variant, Low microbial diversity; butyrate capacity 41/100, diversity 2.7. Pushing it down: Low butyrate capacity (-36.8), 4 keystone species absent (-27.5), Ultra-processed food (-25.7). Pulling it up: Protein (supports) (+27.7). From the daily log: ultra-processed +5.8 GI next day, protein -5.5 GI next day, fat +5.1 GI next day, simple carbs +5.1 GI next day.
Past actions: CR-01 on day 123 → improved (8%).
Next: GI-04 — 90% of 284 similar trajectories improved, 59% probability here. This would be contradicted by a further GI rise within the onset window or falling adherence.
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and events- Day 0 META-24 started — Baseline state S11
- Day 22 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 122 CR-01 recommended — Clinician Review CR-01
- Day 123 Patient accepted — Started CR-01 in the companion
- Day 128 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory began diverging from predicted response on Day 22.
- Inflammatory activity+10
- Toxicity-9
- GI instability+5
- Treatment adherence-4
- Nutritional resilience-3
What helped?
- Clinician Review CR-01Day 122Result: deterioration detected before clinical escalation
- 284 similar trajectories
- 90% showed improvement
- median effect visible after 8 days
Daily trackers
Asset settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Heading towards failing · 38 from the failing basin, 57 from restoration.
- ME-01 Monitoring Escalation100% improved among 45 similar · onset 3 d · confidence 61%
- GI-04 GI Support Protocol67% improved among 67 similar · onset 8 d · confidence 52%
- NP-02 Dietary Support Protocol62% improved among 37 similar · onset 10 d · confidence 61%
- More proteinGI -5.5 next day on high-intake days · n 19
- Keep ultra-processed lowGI +5.8 next day on high-intake days · n 16
- Keep fat lowGI +5.1 next day on high-intake days · n 21
- Keep simple carbs lowGI +5.1 next day on high-intake days · n 19
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Ultra-processed food+5.8detractor · 95%
- Protein-5.5supporter · 95%
- Dietary fat load+5.1detractor · 95%
- Simple carbohydrates+5.1detractor · 95%
- Alcohol+4detractor · 95%
- Insoluble fibre+0.5no signal · 15%
DeepGene damage signature
The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.
- 2 opportunists above range: Streptococcus gallolyticus, Clostridioides difficile
- 4 keystone species absent
- Shannon 2.38 (expected ≥ 3)
- 8 resistance genes
- Host DNA fragmentation atypical
- Tissue recycling index 46
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 63
- WearableHRV 23 ms, trending down
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 41/100
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓20
- Daily logGI symptom score 53 and rising
- Drug metabolism and exposure ↑20
- BloodToxicity index 52
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Rapid metabolizerExpected exposure
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
- HRV
- 24 ms
- Sleep
- 7.3 h
- Steps
- 3,733
- Resting HR
- 66 bpm
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02274 | 56% | S10 | CR-01 | improved | 58 |
| P-02211 | 55% | S11 | CR-01 | improved | 56 |
| P-02027 | 54% | S11 | CR-01 | improved | 62 |
| P-02405 | 54% | S11 | GI-04 | no change | 60 |
| P-02113 | 50% | S02 | — | — | 59 |
| P-02645 | 48% | S11 | GI-04 | improved | 60 |
| P-02035 | 47% | S11 | — | — | 62 |
| P-02139 | 45% | S02 | CR-01 | improved | 61 |
| P-02263 | 45% | S01 | CR-01 | improved | 62 |
| P-02317 | 45% | S04 | CR-01 | improved | 58 |
| P-02473 | 44% | S01 | CR-01 | improved | 56 |
| P-02510 | 44% | S13 | GI-04 | improved | 61 |